[go: up one dir, main page]

WO2006008660A3 - Streptococcus pneumoniae enoyl- (acyl-carrier-protein) reductase (fabk) - Google Patents

Streptococcus pneumoniae enoyl- (acyl-carrier-protein) reductase (fabk) Download PDF

Info

Publication number
WO2006008660A3
WO2006008660A3 PCT/IB2005/003287 IB2005003287W WO2006008660A3 WO 2006008660 A3 WO2006008660 A3 WO 2006008660A3 IB 2005003287 W IB2005003287 W IB 2005003287W WO 2006008660 A3 WO2006008660 A3 WO 2006008660A3
Authority
WO
WIPO (PCT)
Prior art keywords
fabk
reductase
acyl
protein
carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2005/003287
Other languages
French (fr)
Other versions
WO2006008660A2 (en
Inventor
Akil Dharamsi
Aled Edwards
Simon Houston
Dhushy Kanagarajah
Vladimir Romanov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affinium Pharmaceuticals Inc
Original Assignee
Affinium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affinium Pharmaceuticals Inc filed Critical Affinium Pharmaceuticals Inc
Publication of WO2006008660A2 publication Critical patent/WO2006008660A2/en
Publication of WO2006008660A3 publication Critical patent/WO2006008660A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/001—Oxidoreductases (1.) acting on the CH-CH group of donors (1.3)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to polypeptide targets for pathogenic bacteria, especially enoyl-(acyl-carrier-protein) reductase (FabK) from Staphylococcus pneumoniae. The invention provides purified, soluble forms of FabK polypeptide suitable for structural and functional characterization by mass spectrometry, NMR and X-ray crystallography, as well as rational drug design based on the structural information obtained.
PCT/IB2005/003287 2004-07-20 2005-07-20 Streptococcus pneumoniae enoyl- (acyl-carrier-protein) reductase (fabk) Ceased WO2006008660A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58951004P 2004-07-20 2004-07-20
US60/589,510 2004-07-20

Publications (2)

Publication Number Publication Date
WO2006008660A2 WO2006008660A2 (en) 2006-01-26
WO2006008660A3 true WO2006008660A3 (en) 2006-10-26

Family

ID=35785598

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/003287 Ceased WO2006008660A2 (en) 2004-07-20 2005-07-20 Streptococcus pneumoniae enoyl- (acyl-carrier-protein) reductase (fabk)

Country Status (1)

Country Link
WO (1) WO2006008660A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005005469A2 (en) 2003-07-11 2005-01-20 Affinium Pharmaceuticals, Inc. Novel purified polypeptides from staphylococcus aureus
KR101831674B1 (en) 2007-08-06 2018-02-23 밀레니엄 파머슈티컬스 인코퍼레이티드 Proteasome inhibitors
US7797112B2 (en) * 2007-12-28 2010-09-14 Korea Institute Of Science And Technology Method of identifying a FabK protein inhibitor using a three-dimensional structure of FabK protein
CN102066386A (en) 2008-06-17 2011-05-18 米伦纽姆医药公司 Borate compound and its pharmaceutical composition
CN102946879B (en) 2010-04-19 2015-04-22 尼基制药公司 Application of a kind of proteasome inhibitor and gallium complex in the preparation of medicines for treating proliferative diseases
MA41505A (en) 2015-02-11 2017-12-19 Millennium Pharm Inc NEW CRYSTALLINE FORM OF A PROTEASOME INHIBITOR

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002031128A1 (en) * 2000-10-06 2002-04-18 Smithkline Beecham Corporation Methods of agonizing and antagonizing fabk
US6613553B1 (en) * 2000-02-04 2003-09-02 St. Jude Children's Research Hospital Enoyl reductases and methods of use thereof
WO2003102190A2 (en) * 2002-05-31 2003-12-11 Affinium Pharmaceuticals, Inc. Bacterial polypeptides involved in viability

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613553B1 (en) * 2000-02-04 2003-09-02 St. Jude Children's Research Hospital Enoyl reductases and methods of use thereof
WO2002031128A1 (en) * 2000-10-06 2002-04-18 Smithkline Beecham Corporation Methods of agonizing and antagonizing fabk
WO2003102190A2 (en) * 2002-05-31 2003-12-11 Affinium Pharmaceuticals, Inc. Bacterial polypeptides involved in viability

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
COURCHESNE P L ET AL: "Identification of Proteins by Matrix-Assisted Laser Desorption/Ionization Mass Spectroscopy Using Peptide and Fragment Ion Masses (from 2-D Proteome Analysis Protocols, Ed. A. J. Link)", METHODS IN MOLECULAR BIOLOGY, HUMANA PRESS INC., CLIFTON, NJ, US, vol. 112, 1999, pages 487 - 511, XP002103063 *
DATABASE EMBL [online] 10 August 2000 (2000-08-10), "Streptococcus pneumoniae fab gene cluster, complete sequence", XP002387418, Database accession no. AF197933 *
HEATH R J ET AL: "A triclosan-resistant bacterial enzyme", NATURE, NATURE PUBLISHING GROUP, LONDON, GB, vol. 406, 13 July 2000 (2000-07-13), pages 145 - 146, XP000993256, ISSN: 0028-0836 *
KAY L E: "Nuclear Magnetic Resonance Methods for High Molecular Weight Proteins: A Study Involving a Complex of Maltose Binding Protein and Beta-Cyclodextrin", METHODS IN ENZYMOLOGY, ACADEMIC PRESS INC, SAN DIEGO, CA, US, vol. 339, 2001, pages 174 - 203, XP001152928, ISSN: 0076-6879 *
MARRAKCHI HEDIA ET AL: "Characterization of Streptococcus pneumoniae enoyl-(acyl-carrier protein) reductase (FabK).", BIOCHEMICAL JOURNAL, vol. 370, no. 3, 15 March 2003 (2003-03-15), pages 1055 - 1062, XP002387412, ISSN: 0264-6021 *
QUI X ET AL: "Molecular basis for triclosan activity involves a flipping loop in the active site", PROTEIN SCIENCE, CAMBRIDGE UNIVERSITY PRESS, CAMBRIDGE, GB, vol. 8, no. 11, November 1999 (1999-11-01), pages 2529 - 2532, XP001205990, ISSN: 0961-8368 *
RODGERS D W: "Cryocrystallography.", STRUCTURE (LONDON, ENGLAND) 15 DEC 1994, vol. 2, no. 12, 15 December 1994 (1994-12-15), pages 1135 - 1140, XP002387413, ISSN: 0969-2126 *

Also Published As

Publication number Publication date
WO2006008660A2 (en) 2006-01-26

Similar Documents

Publication Publication Date Title
WO2009146218A3 (en) Compounds including an anti-inflammatory pharmacore and methods of use
WO2006092213A8 (en) Pyrazolylcarboxanilides
WO2007031548A3 (en) Processes for preparing of glucopyranosyl-substituted (ethynyl-benzyl)-benzene derivatives and intermediates thereof
WO2004082619A3 (en) Forms of 5-azacytidine
WO2004082822A3 (en) Methods for isolating crystalline form i of 5-azacytidine
MX2007013632A (en) Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein.
MX2007005221A (en) Ascomycin crystalline forms and preparation thereof.
WO2007127292A3 (en) Tigeycline crystalline forms and processes for preparation thereof
WO2006128150A3 (en) Crystalline solid forms of tigecycline and methods of preparing same
WO2006130501A3 (en) Tigecycline and methods of preparing 9-nitrominocycline
WO2007031858A3 (en) An improved process for the preparation of beta-lactam antibiotic
WO2006130500A3 (en) Tigecycline and methods of preparing 9-aminominocycline
WO2007098273A3 (en) Novel crystalline forms of armodafinil and preparation thereof
NO20081617L (en) Methods for Preparation of Glutamic Acid Derivatives
WO2006008660A3 (en) Streptococcus pneumoniae enoyl- (acyl-carrier-protein) reductase (fabk)
WO2007115929A8 (en) Thiazolyl-dihydroquinazolines
WO2005054172A3 (en) Jasmonate derivative compounds, pharmaceuticals compositions and methods of use thereof
WO2007062370A3 (en) Calcilytic compounds
WO2007004092A3 (en) Novel intermediates, process for their preparation and process for the preparation of coq10 employing the said novel intermediates
WO2007047671A3 (en) Tetrahydroquinolines, synthesis thereof, and intermediates thereto
WO2007016029A3 (en) Diazepinoquinolines, synthesis thereof, and intermediates thereto
WO2010091109A3 (en) Tuned synthetic dendrimer calibrants for mass spectrometry
CA2585802A1 (en) Industrial process for the preparation of 17-hydroxy-6.beta.,7.beta.;15.beta.,16.beta.-bismethylene-3-oxo-17.alpha.pregn-4-ene-21-carboxylic acid.gamma.-lactone and key-intermediates for this process
WO2008015133A3 (en) Process for preparing amidrazones
WO2007066158A3 (en) HIGH PURITY 17α-CYANOMETHYL-17β-HYDROXY-ESTRA-4,9-DIENE-3-ONE AND PROCESS FOR THE SYNTHESIS THEREOF

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase